Kriya Therapeutics is a next-generation gene therapy company focused on designing and developing transformative gene therapies for highly prevalent serious diseases.
Kriya's mission is to expand the reach of gene therapy to address highly prevalent diseases affecting millions of patients.
Kriya Therapeutics was founded in 2019 by Shankar Ramaswamy, Roger Jeffs and John Fraser Wright. The company is headquartered in Palo Alto, California.
Kriya is targeting diseases where the underlying biology is well-understood, with the goal of rationally designing one-time gene therapies to durably express therapeutic proteins within the appropriate human tissues.
Kriya uses algorithmic tools, scalable infrastructure, and proprietary technology to optimize the efficacy and durability of its gene therapies.
Kriya is establishing a platform for the development of gene therapies targeting serious chronic diseases affecting millions of patients. The company's initial pipeline includes multiple programs for the treatment of metabolic diseases including type 1 diabetes, type 2 diabetes, and severe obesity.
Kriya Therapeutics has raised $80.5M in a Series A round on May 12, 2020. Investors included QVT, Dexcel Pharma, Foresite Capital, Bluebird Ventures (associated with Sutter Hill Ventures), Narya Capital, Amplo, Paul Manning, Transhuman Capital and Asia Alpha.